FY2024 EPS Estimates for Imunon Increased by Zacks Small Cap

Imunon, Inc. (NASDAQ:IMNN) – Stock analysts at Zacks Small Cap raised their FY2024 EPS estimates for Imunon in a research report issued on Monday, November 11th. Zacks Small Cap analyst D. Bautz now forecasts that the company will post earnings per share of ($1.74) for the year, up from their previous estimate of ($1.90). The consensus estimate for Imunon’s current full-year earnings is ($1.68) per share.

A number of other equities research analysts have also recently weighed in on IMNN. HC Wainwright dropped their price target on Imunon from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday. EF Hutton Acquisition Co. I upgraded Imunon to a “strong-buy” rating in a report on Monday, September 23rd.

Imunon Stock Performance

Shares of NASDAQ:IMNN opened at $0.75 on Wednesday. The company has a 50-day simple moving average of $1.00 and a 200 day simple moving average of $1.19. The company has a market capitalization of $44.84 million, a P/E ratio of -0.40 and a beta of 2.14. Imunon has a 52-week low of $0.48 and a 52-week high of $3.65.

Imunon (NASDAQ:IMNN) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.04.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.